ClinicalTrials.gg
RecruitingNCT07486817Updated Nov 9, 2026

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

A Phase 2 interventional study of Zongertinib and Cisplatin in Lung Cancer, Non-squamous, Non-small Cell, sponsored by Boehringer Ingelheim. Recruiting at 20 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 9, 2026First site in United Kingdom4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing pembrolizumab in Lung Neoplasms — 10 open to participants now, 22 under way, 9 of them phase 3. pembrolizumab · Lung Neoplasms.

Planned enrollment
16th of 39
60 · median 46
Started
2026
with 1 other
Phase 2
22 of 39
5 open now
Primary completion
2027-08
later than 9 of 21 live
Registered
39th of 39
by date
Lead sponsor
1 of 39
Boehringer Ingelheim

Among the 39 studies testing pembrolizumab in Lung Neoplasms, this one is the 16th largest by planned enrollment, is one of 2 that started in 2026, is one of 22 in phase 2, reaches primary completion later than 9 of the 21 other live ones, and was the 39th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

10 of the 39 studies testing pembrolizumab in Lung Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing pembrolizumab in Lung Neoplasms, or all of them as a file.
02

Study summary

This study is open to adults with a type of lung cancer called HER2-mutant non-squamous non-small cell lung cancer (NSCLC) that is advanced or has spread. People who have a tumor with a HER2 mutation and have not received previous treatment for their lung cancer can participate in the study. The purpose of this study is to find out how well a medicine called zongertinib is tolerated in people with this type of lung cancer, when combined with chemotherapy, with or without pembrolizumab. Zongertinib works by targeting and blocking HER2, a protein involved in cancer cell growth.

Participants are put into two groups randomly, which means by chance. One group gets zongertinib tablets combined with platinum-based chemotherapy. The other group gets the same treatment plus an additional medicine called pembrolizumab. Chemotherapy and pembrolizumab are given as an infusion into a vein. Participants take zongertinib by mouth once a day, while chemotherapy is given every 3 weeks for up to 3 months, followed by maintenance treatment for up to 2 years.

Pembrolizumab is given every 3 weeks for up to 2 years.

This study does not have a fixed duration. Participants can receive some of the study treatments for up to about 2 years and may continue to take zongertinib as long as they benefit from treatment and can tolerate it. During this time, they visit the study site regularly. Doctors regularly check the size of the tumor and whether it has spread. They also monitor participants' health and take note of any unwanted effects.

03

Conditions studied

  • Lung Cancer, Non-squamous, Non-small Cell

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the form (ICF)
  2. or cytologically confirmed diagnosis of an advanced and/or non-squamous non-small cell lung cancer (NSCLC)
  3. Documented activating human epidermal growth factor receptor 2 () mutation as per existing local lab result
  4. An sample must be submitted to the central laboratory after randomization to retrospectively confirm the HER2 status
  5. Patients who have not received any systemic treatment for unresectable, locally advanced or metastatic disease
  6. Presence of at least one measurable non-Central Nervous System (CNS) lesion according to (RECIST) 1.1
  7. Eligible to receive treatment with the selected platinum based doublet chemotherapy and pembrolizumab in accordance with the summary of product characteristics (SmPC)/Product Information
  8. (ECOG) score of 0 or 1 Further inclusion criteria apply.

Exclusion criteria

Exclusion criteria:

  1. Tumors with targetable alterations with approved available therapy
  2. Presence or history of
  3. Radiotherapy within 4 weeks prior to treatment start with exception of palliative radiotherapy to regions other than the chest if completed at least 2 weeks prior to treatment start
  4. Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to randomization or planned within 6 months after screening
  5. Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the trial or interfere with the evaluation of the safety and efficacy of the test drug
  6. Previous therapy with a -directed agent
  7. History or presence of cardiovascular abnormalities which are considered as by the investigator. Myocardial infarction, stroke, or pulmonary embolism within 6 months prior to randomization Further exclusion criteria apply.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Arm A: zongertinib + cisplatin or carboplatin and pemetrexed

    Drug: Zongertinib · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    Arm B: zongertinib + cisplatin or carboplatin and pemetrexed with pembrolizumab

    Drug: Zongertinib · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Occurrence of discontinuation and/or prolonged interruption (>7 days) of zongertinib due to treatment-related adverse events (AEs) in the first 2 cycles of treatment

    Time frame: up to 6 weeks

Secondary outcomes

  1. Occurrence of serious adverse events (SAE) during the on-treatment period

    Time frame: up to 1.5 years

  2. Occurrence of dose reduction of zongertinib

    Time frame: up to 1.5 years

  3. Occurrence of discontinuation and/or prolonged interruption (>7 days) of zongertinib due to treatment-related AEs during the on-treatment period

    Time frame: up to 1.5 years

  4. Occurrence of Grade ≥3 non-hematological AE during the on-treatment period

    Time frame: up to 1.5 years

  5. Occurrence of combination limiting toxicities (CLTs) during the on-treatment period

    Specific adverse events (AEs) are classified as combination limiting toxicities (CLTs) in the study protocol, e.g.: * laboratory parameters that exceed predefined limits as defined in the study protocol \* * Treatment-related death (other than death related to progressive disease) * Any AE which causes an interruption or delay to treatment with zongertinib of greater than 7 days * Any AE that requires treatment discontinuation of zongertinib in accordance with the study protocol

    Time frame: up to 1.5 years

  6. Objective response (OR) according to Response evaluation criteria in solid tumors (RECIST) 1.1 as assessed by the investigator

    OR is defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) from date of randomization until the earliest of disease progression, death, or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent

    Time frame: up to 1.5 years

  7. Time to OR, defined as the time from date of randomization to first documented confirmed CR or PR among patients with OR as determined by investigator assessment per RECIST 1.1

    Time frame: up to 1.5 years

  8. Duration of OR (DoR), defined as the time from first documented confirmed CR or PR until disease progression or death among patients with OR as determined by investigator assessment per RECIST 1.1

    Time frame: up to 1.5 years

  9. Progression-free survival (PFS), defined as the time from randomization until tumor progression according to RECIST 1.1 as assessed by the investigator, or death from any cause, whichever occurs earlier

    Time frame: up to 1.5 years

  10. Time on treatment (ToT), defined as the time from first dose of study treatment until zongertinib treatment discontinuation or death

    Time frame: up to 1.5 years

07

Study locations

19 of 20 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Aug 2027, 14 months after the start.

Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 14 months is below that.

Counting every sponsor, half of 364 studies reached it within 65 months; a quarter within 34 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 23, 2026
StartActual
Jun 4, 2026
Primary completionEst.
Aug 12, 2027
CompletionEst.
Aug 25, 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 1 site removed — first site in United Kingdom
Show 4 added (3 United Kingdom, 1 Spain)
  • Hospital Universitario Virgen del Rocio · Seville, Spain
  • St James's University Hospital · Leeds, United Kingdom
  • The Royal Marsden Hospital, Chelsea · London, United Kingdom
  • The Royal Marsden Hospital, Sutton · Sutton, United Kingdom
Show 1 removed
  • Hospital Virgen del Rocío · Seville, Spain
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    4 sites added, 1 site removed — first site in United Kingdom
    Show 4 added (3 United Kingdom, 1 Spain)
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    • St James's University Hospital · Leeds, United Kingdom
    • The Royal Marsden Hospital, Chelsea · London, United Kingdom
    • The Royal Marsden Hospital, Sutton · Sutton, United Kingdom
    Show 1 removed
    • Hospital Virgen del Rocío · Seville, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07486817
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Jun 4, 2026
Primary completion
Aug 12, 2027 (estimated)
Completion
Aug 25, 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
18002430127

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zongertinib · Pembrolizumab

Start the discussion